Compounds for use as iron(III) MRI contrast agents
US-11261208-B2 · Mar 1, 2022 · US
US12534487B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12534487-B2 |
| Application number | US-202217682695-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 28, 2022 |
| Priority date | May 19, 2017 |
| Publication date | Jan 27, 2026 |
| Grant date | Jan 27, 2026 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Provided are macrocyclic compounds and compounds with two or more macrocyclic groups, iron coordinated macrocyclic compounds, and iron coordinated compounds with two or more macrocyclic groups. The iron is high-spin iron(III). The iron coordinated compounds may exhibit a negative redox potential (e.g., relative to a normal hydrogen electrode at a biologically relevant pH, for example, a pH of 6.5-7.5). The compounds can be used as MRI contrast agents.
Opening claim text (preview).
The invention claimed is: 1 . A macrocyclic core having the following structure: and Z 1 , Z 2 , and Z 3 are each independently H or one or more of the following pendant groups: or a deprotonated analog thereof or a stereoisomer thereof, wherein R is methyl, and Ri is independently a substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted alkyl group, and R 1 is not pendant donors; Q 4 and Q 5 are each independently H, OCH 3 , CO 2 H, or substituted or unsubstituted alkyl groups of linear or branched structures, A is a substituted or unsubstituted alkyl group of linear or branched structure with C 1 to C 12 or is a substituted or unsubstituted aryl group or an amino acid, or a salt, a partial salt, a hydrate, a polymorph, or a stereoisomer thereof, wherein the macrocyclic core has structure II or III, Z 1 and Z 2 are each independently a pendant group; wherein for all structures I, II, and III, each of Z 1 , Z 2 , and Z 3 , as applicable, are selected independently of each other, and at least one of R, Z 1 , Z 2 , and Z 3 is different than the remaining R, Z 1 , Z 2 , and Z 3 . 2 . The macrocyclic core of claim 1 , wherein the macrocyclic core has the following structure: and at least one anionic pendant group. 3 . The macrocyclic core of claim 1 , wherein the macrocyclic core has the following structure: 4 . A macrocyclic core having the following structure:
the protein being an albumin, e.g. HSA, BSA, ovalbumin · CPC title
comprising multiple complex or complex-forming groups, being either part of the linear polymeric backbone or being pending groups covalently linked to the linear polymeric backbone · CPC title
dendrimers, dendrons, hyperbranched compounds · CPC title
the complex-forming compound being cyclic, e.g. DOTA · CPC title
conjugated systems · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.